{"filing":{"accession_number":"0001213900-26-088029","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"ea0301726-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026088029/ea0301726-6k_canfite.htm"},"events":[{"id":27018,"run_id":24584,"accession_number":"0001213900-26-088029","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces regulatory milestones for two Phase III drug candidates: Namodenoson's FDA Fast Track and Orphan Drug designations for hepatocellular carcinoma, and Piclidenoson's advancement in Phase III development for psoriasis. While these are significant clinical and regulatory achievements that would inform a reasonable investor's assessment of the company's pipeline maturity and approval pathways, they do not constitute a discrete event type (such as earnings, M\u0026A, or executive changes) but rather represent operational progress in clinical development. The disclosure emphasizes \"established regulatory pathways\" and \"advanced regulatory status\" as strategic achievements, making this an operational/clinical milestone rather than a financial or governance event.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-08-12","form":"6-K","submitted_at":null,"items":[{"id":28356,"accession_number":"0001213900-26-088029","item_number":"EX-99.1","item_title":"ea030172601ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces regulatory milestones for two Phase III drug candidates: Namodenoson's FDA Fast Track and Orphan Drug designations for hepatocellular carcinoma, and Piclidenoson's advancement in Phase III development for psoriasis. While these are significant clinical and regulatory achievements that would inform a reasonable investor's assessment of the company's pipeline maturity and approval pathways, they do not constitute a discrete event type (such as earnings, M\u0026A, or executive changes) but rather represent operational progress in clinical development. The disclosure emphasizes \"established regulatory pathways\" and \"advanced regulatory status\" as strategic achievements, making this an operational/clinical milestone rather than a financial or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:05:09.793863+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28356,"accession_number":"0001213900-26-088029","item_number":"EX-99.1","item_title":"ea030172601ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces regulatory milestones for two Phase III drug candidates: Namodenoson's FDA Fast Track and Orphan Drug designations for hepatocellular carcinoma, and Piclidenoson's advancement in Phase III development for psoriasis. While these are significant clinical and regulatory achievements that would inform a reasonable investor's assessment of the company's pipeline maturity and approval pathways, they do not constitute a discrete event type (such as earnings, M\u0026A, or executive changes) but rather represent operational progress in clinical development. The disclosure emphasizes \"established regulatory pathways\" and \"advanced regulatory status\" as strategic achievements, making this an operational/clinical milestone rather than a financial or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:05:09.793863+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-08-12"}]}